Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference May 23, 2022
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 May 19, 2022
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference May 19, 2022
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency May 13, 2022
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress May 12, 2022
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 10, 2022
